Poxel SA
π«π·France
- Country
- π«π·France
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.poxelpharma.com
Safety, Tolerability and PK of PXL770 in Healthy Male Subjects
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 60
- Registration Number
- NCT03395470
- Locations
- π¬π§
Hammersmith Medicines Research (HMR), London, United Kingdom
Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 55
- Registration Number
- NCT02924337
- Locations
- π¬π§
Hammersmith Medicines Research (HMR), London, United Kingdom
Safety, Tolerability and PK of Imeglimin in Japanese Volunteers
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 48
- Registration Number
- NCT02373150
- Locations
- π¬π§
Hammersmith Medicines Research (HMR), London, United Kingdom
A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 315
- Registration Number
- NCT01951235
- Locations
- π±π»
Pauls Stradins Clinical University Hospital, Riga, Latvia
Β© Copyright 2024. All Rights Reserved by MedPath